1-Tosylpiperazine hydrochloride

Catalog No.: 
ACBYOM762
CAS No.: 
856843-84-0
Molecular Formula: 
C11H17ClN2O2S
Molecular Weight: 
276.79
1-Tosylpiperazine hydrochloride structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
25g98%$124.00In stockIn stock
100g98%$441.00InquiryIn stock
500g98%$1940.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-Tosylpiperazine hydrochloride
IUPAC Name1-tosylpiperazine hydrochloride
MDL No.MFCD03540891
Molecular FormulaC11H17ClN2O2S
Molecular Weight276.79
SMILESO=S(N1CCNCC1)(C2=CC=C(C)C=C2)=O.[H]Cl
InChI KeyIMLDHDNEYHSNDL-UHFFFAOYSA-N
Synonym1-Tosylpiperazine hydrochloride;1-(TOLUENE-4-SULFONYL)-PIPERAZINE HYDROCHLORIDE;1-(4-methylbenzenesulfonyl)piperazine hydrochloride;1-Tosylpiperazine, HCl;1-Tosylpiperazine hydrochloride, 98%
CAS No.856843-84-0
PubChem CID46743459

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H315-H319-H335
Precautionary Statement(s)
P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACBYOM762 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACEUMO414 route compound structure diagram
    ACEUMO41459813-05-7
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACBYOM762 route product structure diagram
    ACBYOM762856843-84-0In Stock
Inquiry

2. ACBYOM762 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACBYOM762 route product structure diagram
    ACBYOM762856843-84-0In Stock
Inquiry

3. ACBYOM762 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACBYOM762 route product structure diagram
    ACBYOM762856843-84-0In Stock
Inquiry

Comments (0)